<p>在過去三個月中，5 位分析師對 4D Molecular Therapeutics（納斯達克：FDMT）發佈了評級，展現了從看漲到看跌的廣泛觀點。</p>
<p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 30.0 美元，最高預估為 33.00 美元，最低預估為 26.00 美元。當前平均價格目標較之前的 28.75 美元上升了 4.35%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png"/></p>
<h2>理解分析師評級：全面解析</h2>
<p>通過對最近分析師行動的深入分析，4D Molecular Therapeutics 在金融專家中的地位變得清晰。下面的總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>發佈</td>
<td>超配</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>維持</td>
<td>買入</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超過市場</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>上調</td>
<td>買入</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現的變化，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 4D Molecular Therapeutics 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “超過市場” 到 “低於市場”。這些評級反映了對 4D Molecular Therapeutics 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師探討價格目標的動態，提供對 4D Molecular Therapeutics 股票未來價值的估計。這一研究揭示了分析師預期隨時間的變化。</li>
</ul>
<p>為了獲取關於 4D Molecular Therapeutics 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 4D Molecular Therapeutics 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>探索 4D Molecular Therapeutics：更深入的瞭解</h2>
<p>4D Molecular Therapeutics Inc 是一家臨牀階段基因治療公司，專注於使用靶向和進化的 AAV 載體開發產品候選者。它建立了一個基因治療產品候選者的組合，專注於三個治療領域：眼科（玻璃體內載體）包括 4D-150、4D-125、4D-110 和 4D-175；心臟病學（靜脈載體）包括 4D-710、4D-725；以及肺病學（氣霧劑載體）4D-310。</p>
<h3>4D Molecular Therapeutics：財務表現解析</h3>
<p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，反映出其規模龐大和市場認可度強。</p>
<p><strong>積極的收入趨勢：</strong> 對 4D Molecular Therapeutics 的財務數據進行 3 個月的審查，揭示了積極的敍述。截止 2025 年 9 月 30 日，該公司實現了 <strong>2900.0%</strong> 的顯著收入增長率，展示了頂線收益的顯著增加。與同行相比，該公司的增長率高於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> 4D Molecular Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面面臨挑戰。淨利潤率為 <strong>-63195.56%</strong>，公司可能在有效成本管理方面面臨困難。</p>
<p><strong>股本回報率（ROE）：</strong> 4D Molecular Therapeutics 的 ROE 超出行業基準，達到 <strong>-14.4%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
<p><strong>資產回報率（ROA）：</strong> 4D Molecular Therapeutics 的 ROA 低於行業平均水平，表明在有效利用資產方面面臨挑戰。ROA 為 <strong>-12.67%</strong>，公司可能在從資產中產生最佳回報方面面臨困難。</p>
<p><strong>債務管理：</strong> 4D Molecular Therapeutics 的債務與股本比率低於行業平均水平。該比率為 <strong>0.06</strong>，公司對債務融資的依賴較低，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<h2>分析師評級基礎知識</h2>
<p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度對每隻股票進行一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
<p>除了他們的評估，一些分析師通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

生物科技 ETF - VanEck Vectors

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>在過去三個月中，5 位分析師對 4D Molecular Therapeutics（NASDAQ:FDMT）進行了評級，顯示出從看漲到看跌的情緒混合。12 個月的平均目標價為 30.00 美元，比 28.75 美元上漲了 4.35%。分析師的行動包括上調和下調評級，反映了市場狀況。該公司的市值高於行業平均水平，報告了 2900% 的收入增長率，儘管面臨淨利潤率為-63195.56% 的挑戰。其債務與股本比率為 0.06，表明對債務融資的依賴較小</p>

<p>In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ: FDMT), presenting a wide array of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，5 位分析師對 4D Molecular Therapeutics（納斯達克：FDMT）發佈了評級，展現了從看漲到看跌的廣泛觀點。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.0, a high estimate of $33.00, and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 4.35% from the previous average price target of $28.75.</p>
<div class="lb-trans"><p>分析師評估的 12 個月價格目標揭示了進一步的見解，平均目標為 30.0 美元，最高預估為 33.00 美元，最低預估為 26.00 美元。當前平均價格目標較之前的 28.75 美元上升了 4.35%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769608879_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769608879_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析師評級：全面解析</h2>
</div><p>The standing of 4D Molecular Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的深入分析，4D Molecular Therapeutics 在金融專家中的地位變得清晰。下面的總結概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>發佈</td>
<td>超配</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>維持</td>
<td>買入</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lisa Walter</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超過市場</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>上調</td>
<td>買入</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現的變化，頻繁更新他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 4D Molecular Therapeutics 最近發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “超過市場” 到 “低於市場”。這些評級反映了對 4D Molecular Therapeutics 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師探討價格目標的動態，提供對 4D Molecular Therapeutics 股票未來價值的估計。這一研究揭示了分析師預期隨時間的變化。</li>
</ul>
</div><p>For valuable insights into 4D Molecular Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲取關於 4D Molecular Therapeutics 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on 4D Molecular Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 4D Molecular Therapeutics 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>Discovering 4D Molecular Therapeutics: A Closer Look</h2>
<div class="lb-trans"><h2>探索 4D Molecular Therapeutics：更深入的瞭解</h2>
</div><p>4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics Inc 是一家臨牀階段基因治療公司，專注於使用靶向和進化的 AAV 載體開發產品候選者。它建立了一個基因治療產品候選者的組合，專注於三個治療領域：眼科（玻璃體內載體）包括 4D-150、4D-125、4D-110 和 4D-175；心臟病學（靜脈載體）包括 4D-710、4D-725；以及肺病學（氣霧劑載體）4D-310。</p>
</div><h3>4D Molecular Therapeutics: Financial Performance Dissected</h3>
<div class="lb-trans"><h3>4D Molecular Therapeutics：財務表現解析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，反映出其規模龐大和市場認可度強。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining 4D Molecular Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2900.0%</strong> as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>積極的收入趨勢：</strong> 對 4D Molecular Therapeutics 的財務數據進行 3 個月的審查，揭示了積極的敍述。截止 2025 年 9 月 30 日，該公司實現了 <strong>2900.0%</strong> 的顯著收入增長率，展示了頂線收益的顯著增加。與同行相比，該公司的增長率高於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> 4D Molecular Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-63195.56%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 4D Molecular Therapeutics 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面面臨挑戰。淨利潤率為 <strong>-63195.56%</strong>，公司可能在有效成本管理方面面臨困難。</p>
</div><p><strong>Return on Equity (ROE):</strong> 4D Molecular Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-14.4%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 4D Molecular Therapeutics 的 ROE 超出行業基準，達到 <strong>-14.4%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> 4D Molecular Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-12.67%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 4D Molecular Therapeutics 的 ROA 低於行業平均水平，表明在有效利用資產方面面臨挑戰。ROA 為 <strong>-12.67%</strong>，公司可能在從資產中產生最佳回報方面面臨困難。</p>
</div><p><strong>Debt Management:</strong> 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.06</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 4D Molecular Therapeutics 的債務與股本比率低於行業平均水平。該比率為 <strong>0.06</strong>，公司對債務融資的依賴較低，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析師評級基礎知識</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>評級來自分析師，或在銀行和金融系統內的專家，他們為特定股票或定義的行業報告（通常每季度對每隻股票進行一次）。分析師通常從公司電話會議和會議、財務報表以及與重要內部人士的對話中獲取信息，以做出決策。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估，一些分析師通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

benzinga_article

標普全球醫療股指數 ETF - iShares

4D Molecular Therapeutics

Invesco Nasdaq Biotechnology ETF

標普生物技術 ETF - SPDR

醫療業 ETF - Vanguard

動態生物技術與基因組 ETF - Invesco

美國制藥 ETF - iShares

醫療業 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

深入分析 4D Molecular Therapeutics 股票：分析師觀點（5 項評級）